Mr. Dane Stevens reports

OPTIMI HEALTH COMPLETES PSILOCYBIN EXPORT TO AUSTRALIA FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

Optimi Health Corp. has completed its latest export of five-milligram psilocybin finished drug product to Australia, marking its third commercial shipment since the September, 2025, launch of its five-milligram psilocybin capsules.

The shipment included 1,000 capsules of five-milligram psilocybin, which are being prescribed in Australia for treatment-resistant depression, an indication for which regulated patient access is available. TRD refers to major depression that has not responded to multiple standard antidepressant treatments and represents a significant unmet medical need.

"We are proud to be among the few Nasdaq-listed companies commercially supplying psilocybin to patients with treatment-resistant depression outside of clinical trials," said Dane Stevens, chief executive officer and co-founder of Optimi. "Our medicine is produced start to finish in Canada and shipped to pharmacy partners globally, and we are seeing expanding reimbursement coverage from both private and public insurers. We believe Australia is providing an early model for how naturally derived psilocybin can be safely prescribed for TRD in real-world practice, and we are not aware of any serious adverse events reported since inception based on data collected through Dec. 31, 2025."

Australia became the first country in the world to recognize psilocybin as a medicine, rescheduling it from a prohibited substance to a controlled medicine for the treatment of TRD, effective July 1, 2023. MDMA was rescheduled for the treatment of posttraumatic stress disorder on the same day, and Optimi manufactures both psilocybin and MDMA. Patients have since gained broader access under an updated authorized prescriber framework that expanded therapist eligibility and treatment settings, as detailed in the company's news release dated May 29, 2026.

Under the Therapeutic Goods Administration's authorized prescriber scheme, Optimi's psilocybin is being prescribed to patients in Australia and reimbursed by both public and private payers, including the Department of Veterans Affairs, the National Disability Insurance Scheme, WorkCover and Medibank. More than 750 clinicians have been trained to deliver the therapy, and the company is not aware of any serious adverse events that have been reported under the scheme after more than two years of regulated commercial use.

The exported capsules were produced start to finish in-house at Optimi's wholly owned good manufacturing practice facility in Princeton, B.C., Canada, under its Health Canada drug establishment licence, and shipped under export authorization issued by Health Canada. Optimi is among a small number of GMP-licensed manufacturers supplying naturally derived psilocybin to the Australian market, where recurring orders contribute to commercial revenue for the company.

Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, in support of both patient access and clinical research.

About Optimi Health Corp.

Optimi is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program.

We seek Safe Harbor.